---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-103546"
form_type: "8-K"
ticker: "ALUR"
cik: "0001964979"
company_name: "ALLURION TECHNOLOGIES, INC."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:30:21.119086+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Allurion appoints Eli Lilly veteran Keith Johns to Board of Directors

## Summary
- Keith Johns appointed as Class III director effective Sept 2, 2024; board expands from 7 to 8 members.
- Johns spent 25 years at Eli Lilly, most recently leading Global Marketing and Alliance Management for Diabetes and Obesity.
- His expertise includes GLP-1 drug launches and obesity market strategy.
- Compensation will follow standard non-employee director policy as described in prior SEC filings.
- Johns also serves as COO of Adipo Therapeutics, focusing on brown adipose tissue obesity treatments.

## SEC filing metadata
- accession: 0000950170-24-103546
- form_type: 8-K
- ticker: ALUR
- cik: 0001964979
- company_name: ALLURION TECHNOLOGIES, INC.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964979/000095017024103546/0000950170-24-103546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964979/000095017024103546/alur-20240902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-103546
- JSON: https://secwatch.observer/filing/0000950170-24-103546.json
- Plain text: https://secwatch.observer/filing/0000950170-24-103546.txt

## Source-grounded claims
- claim_id: 5843dcf53d
  claim: Keith Johns was appointed as Class III director at ALLURION TECHNOLOGIES, INC..
  evidence_excerpt: On September 2, 2024, the Board of Directors (the "Board") of Allurion Technologies, Inc. ("Allurion" or the "Company") appointed Keith Johns to the Board as a Class III director to fill a vacancy created by an increase in the size of the Board from seven members to eight members, effective September 2, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1964979/000095017024103546/0000950170-24-103546-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.